• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » BioHealth names Chappell first entrepreneur-in-residence

BioHealth names Chappell first entrepreneur-in-residence

March 27, 2012
CenterWatch Staff

BioHealth Innovation (BHI), a new regional private-public partnership, has selected Todd Chappell as the first entrepreneur-in-residence for BHI at the National Institutes of Health (NIH) Office of Technology Transfer (OTT).

Chappell is a venture capital-backed entrepreneurial leader and inventor with more than 10 years of experience in molecular biology research, drug development and life sciences business strategy. Before coming to BHI, he served as the vice president of operations at venture-capital backed Shape Pharmaceuticals, and prior to that he spent nine years at CombinatoRx as director of new products.

As the first entrepreneur-in-residence, Chappell—who will have dual responsibility to both BHI and NIH—will assist OTT in the evaluation of existing technologies, provide an entrepreneurial perspective to OTT in its evaluation of new licensing proposals from start-up companies, advise OTT on opportunities for new ventures based on NIH/FDA technologies, assist with developmental strategies and mentor scientists to help ensure their research becomes commercially valuable.

"There is tremendous start-up potential coming from the 27 institutes of NIH and the FDA research labs,” said Chappell. “With the right strategies and management, new entrepreneurial ventures will be created, and with them, new research, technology and commercially viable health care solutions."

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing